Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

PHATBullishEarningsShort Term

High materiality9/10

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

StockNews.AIJul 30, 6:59 AM EDT1 source

Trading thesisImportance 9/10

Bullish on PHAT over the next 3–6 months as Phase 3 NERD and higher guidance support revenue growth.

AI summary

What happened and why it matters

Phathom reported a record Q2 2026 with $74.3 million revenue and first-time profitability excluding stock-based compensation, while trimming expenses. The company announced a Phase 3 as-needed VOQUEZNA program for NERD and updated full-year guidance, signaling potential market expansion and improved cash flow. Key catalysts include Q4 enrollment for NERD and topline EoE data later in 2026, driving near-term upside for VOQUEZNA.

Record quarterly revenue and near-term profitability could drive multiple expansion.
Phase 3 NERD as-needed program starts enrollment in late 2026, expanding addressable market.
Updated FY2026 net revenue guidance of $310–325M may re-rate growth expectations.
Commercial progress: ~1.7 million VOQUEZNA prescriptions filled by July 17, 2026.

Sentiment rationale

Strong Q2 results with record revenue and near-term profitability ex-SBC; explicit Phase 3 NERD program and EoE data prospects provide tangible catalysts that could push multiple higher, especially if guidance proves durable and cash runway remains robust.

Key facts

01
Q2 2026 net revenues $74.3M; up 88% YoY.
02
VOQUEZNA prescriptions ~1.7M filled; 325k in Q2.
03
Q2 operating expenses $63.1M; down 33% vs 2025.
04
Initiating Phase 3 as-needed VOQUEZNA for NERD; enrollment anticipated Q4 2026.
05
Updated 2026 guidance: net revenue $310–325M; profitability ex-SBC.

Earnings

Category: Earnings. The release centers on quarterly results, updated guidance, and cost discipline, while also detailing pipeline milestones that could influence future revenue trajectories for VOQUEZNA.